Lupin is trading lower by over 4% to Rs 770 on BSE in otherwise firm market after rival Mylan Inc's on Friday launched a generic version of the cholesterol-lowering Tricor in the US.
On Friday, Mylan Inc in a statement said that its subsidiary Mylan Pharmaceuticals Inc has shipped generic Tricor, or fenofibrate tablets, of 48 mg and 145 mg.
Meanwhile, global investment bank Credit Suisse downgraded the stock to "Neutral" from "Outperform" with a target price of Rs 755 per share, the Bloomberg report suggests.
In past ten trading sessions, the stock has outperformed the market by surging 15% compared to 3% rise in benchmark Sensex on reporting a nearly three-fold increase in its consolidated net profit at Rs 408 crore for the fourth quarter ended March 31.
The stock opened at Rs 809 and touched low of Rs 766 on NSE. A combined 1.37 million shares already changed hands on the counter till 1118 hours against an average sub 1.16 million shares that were traded daily in past two weeks on NSE and BSE.
On Friday, Mylan Inc in a statement said that its subsidiary Mylan Pharmaceuticals Inc has shipped generic Tricor, or fenofibrate tablets, of 48 mg and 145 mg.
Meanwhile, global investment bank Credit Suisse downgraded the stock to "Neutral" from "Outperform" with a target price of Rs 755 per share, the Bloomberg report suggests.
In past ten trading sessions, the stock has outperformed the market by surging 15% compared to 3% rise in benchmark Sensex on reporting a nearly three-fold increase in its consolidated net profit at Rs 408 crore for the fourth quarter ended March 31.
The stock opened at Rs 809 and touched low of Rs 766 on NSE. A combined 1.37 million shares already changed hands on the counter till 1118 hours against an average sub 1.16 million shares that were traded daily in past two weeks on NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%